{
  "query_term": "AKEEGA (niraparib/abiraterone)",
  "total_count": 4,
  "returned": 4,
  "kept": 3,
  "studies": [
    {
      "nct_id": "NCT06392841",
      "title": "Hispanic/Latino and Non-Hispanic BlAck Patients Treated With niRaparib and Abiraterone Acetate Plus Prednisone for Metastatic hOrmone Sensitive Prostate Cancer With Deleterious Homologous recombinatioN Repair Alterations: a Phase II, Open Label studY",
      "overall_status": "WITHDRAWN",
      "phase": "Phase 2",
      "conditions": [
        "Metastatic Hormone-sensitive Prostate Cancer (mHSPC)",
        "Deleterious HRR Gene Mutation",
        "BRCA1 Gene Mutation",
        "BRCA2 Gene Mutation",
        "BRIP1 Gene Mutation",
        "CHEK2 Gene Mutation",
        "FANCA Gene Mutation",
        "PALB2 Gene Mutation",
        "RAD51B Gene Mutation",
        "RAD54L Gene Mutation"
      ],
      "lead_sponsor": "Qian Qin",
      "collaborators": [
        "UT Southwestern Comprehensive Cancer Center",
        "Janssen, LP"
      ],
      "interventions": [
        "Androgen Deprivation Therapy (ADT)",
        "Niraparib/Abiraterone Acetate DAT",
        "Abiraterone Acetate",
        "Prednisone",
        "Docetaxel"
      ],
      "last_update": "2025-10-20",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT06392841"
    },
    {
      "nct_id": "NCT06329830",
      "title": "Safety and Anti-tumor Activity of Lutetium-177 (177Lu)-PSMA-617 Along With Niraparib and Abiraterone Acetate Plus Prednisone in Metastatic Castration Resistant Prostate Cancer - LUNAAR Study",
      "overall_status": "WITHDRAWN",
      "phase": "Phase 2",
      "conditions": [
        "Metastatic Prostate Cancer",
        "Castration-resistant Prostate Cancer",
        "Metastatic Castration-resistant Prostate Cancer"
      ],
      "lead_sponsor": "Baptist Health South Florida",
      "collaborators": [
        "Janssen Scientific Affairs, LLC"
      ],
      "interventions": [
        "177Lu-PSMA-617",
        "Niraparib abiraterone acetate",
        "Prednisone"
      ],
      "last_update": "2024-09-19",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT06329830"
    },
    {
      "nct_id": "NCT03903835",
      "title": "ProBio: An Outcome-adaptive and Randomized Multi-arm Biomarker Driven Study in Patients With Metastatic Prostate Cancer",
      "overall_status": "RECRUITING",
      "phase": "Phase 3",
      "conditions": [
        "Metastatic Castration-resistant Prostate Cancer (mCRPC)",
        "Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)"
      ],
      "lead_sponsor": "Karolinska Institutet",
      "collaborators": [
        "The Swedish Research Council",
        "Kom Op Tegen Kanker",
        "Janssen Pharmaceutica N.V., Belgium",
        "AstraZeneca",
        "Cancerfonden"
      ],
      "interventions": [
        "Enzalutamide Oral Capsule",
        "Abiraterone Oral Tablet",
        "Carboplatin",
        "Cabazitaxel 60 mg Solution for Injection",
        "Docetaxel Injectable Solution",
        "Radium Chloride Ra-223",
        "Niraparib plus Abiraterone acetate plus Prednisone",
        "Capivasertib plus Docetaxel",
        "Apalutamide",
        "Darolutamide"
      ],
      "last_update": "2025-04-09",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT03903835"
    }
  ]
}